Novel multimeric IL-1 receptor antagonist for the treatment of rheumatoid arthritis.

Protein therapeutics targeting inflammatory mediators have shown great promise for the treatment of autoimmunities such as rheumatoid arthritis (RA). However, a significant challenge in this area has been their low in vivo stability and consequently their severely compromised therapeutic efficacy. One such therapeutic molecule IL-1 receptor antagonist (IL-1ra), used in the treatment of rheumatoid arthritis, has displayed only modest efficacy in human clinical trials owing to its short biological half-life. Herein, we report a novel approach to conglomerate individual protein entities into a drug depot by incorporation of an amyloidogenic motif Lys-Phe-Phe-Glu (KFFE) thereby dramatically improving their systemic persistence and in turn their therapeutic efficacy in a mice model of autoimmune arthritis.
AuthorsShweta Pasi, Ravi Kant, Sarika Gupta, Avadhesha Surolia
JournalBiomaterials (Biomaterials) Vol. 42 Pg. 121-33 (Feb 2015) ISSN: 1878-5905 [Electronic] Netherlands
PMID25542800 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ltd. All rights reserved.
Chemical References
  • Interleukin 1 Receptor Antagonist Protein
  • Animals
  • Arthritis, Experimental (drug therapy, pathology, radiography)
  • Arthritis, Rheumatoid (drug therapy, pathology, radiography)
  • Cell Line
  • Disease Progression
  • Humans
  • Interleukin 1 Receptor Antagonist Protein (therapeutic use)
  • Mice
  • Microscopy, Atomic Force
  • Protein Multimerization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: